Median TA and TL by presence of selected cytogenetic abnormalities
. | . | Median TA, % of neuroblastoma cell line control . | . | . | Median TL, kbp . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CA . | % . | CA+ . | CA- . | P . | CA+ . | CA- . | P . | ||||
| Translocation 1q-arm | 25 | 26.7 | 6.4 | < .001 | 5.3 | 6.2 | .051 | ||||
| Jumping 1q-arm | 10 | 57.0 | 6.9 | < .001 | 5.0 | 5.8 | .200 | ||||
| Addition 3 | 22 | 44.4 | 6.4 | < .001 | 5.1 | 6.3 | .006 | ||||
| Addition 8 | 5 | 59.1 | 7.5 | .033 | 3.4 | 5.8 | .009 | ||||
| Translocation 8q-arm | 10 | 73.5 | 6.9 | < .001 | 5.1 | 5.7 | .200 | ||||
| Addition 9 | 23 | 19.6 | 6.7 | .003 | 5.4 | 6.1 | .105 | ||||
| Addition 11 | 25 | 15.3 | 6.8 | .037 | 5.1 | 6.2 | .009 | ||||
| Deletion 13 | 25 | 32.1 | 6.9 | .001 | 5.2 | 6.1 | .029 | ||||
| Translocation 14q-arm | 7 | 31.4 | 6.9 | .003 | 4.3 | 5.7 | .115 | ||||
| Deletion 16q-arm | 7 | 60.4 | 7.0 | .005 | 5.1 | 5.7 | .076 | ||||
| Addition 19 | 25 | 48.2 | 6.2 | < .001 | 5.1 | 6.2 | .011 | ||||
| Deletion 19 | 2 | 134.7 | 7.5 | < .001 | 5.4 | 5.6 | .466 | ||||
| Addition 20 | 6 | 70.3 | 7.1 | .006 | 4.0 | 5.7 | .029 | ||||
| Any whole addition | 39 | 23.3 | 5.9 | < .001 | 5.1 | 6.4 | .005 | ||||
| Any whole deletion | 38 | 28.5 | 6.1 | .003 | 5.2 | 6.2 | .027 | ||||
| Any abnormality | 53 | 23.3 | 4.1 | < .001 | 5.1 | 6.6 | < .001 | ||||
| MM-MDS | 20 | 34.9 | 6.8 | < .001 | 4.3 | 6.2 | .001 | ||||
. | . | Median TA, % of neuroblastoma cell line control . | . | . | Median TL, kbp . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CA . | % . | CA+ . | CA- . | P . | CA+ . | CA- . | P . | ||||
| Translocation 1q-arm | 25 | 26.7 | 6.4 | < .001 | 5.3 | 6.2 | .051 | ||||
| Jumping 1q-arm | 10 | 57.0 | 6.9 | < .001 | 5.0 | 5.8 | .200 | ||||
| Addition 3 | 22 | 44.4 | 6.4 | < .001 | 5.1 | 6.3 | .006 | ||||
| Addition 8 | 5 | 59.1 | 7.5 | .033 | 3.4 | 5.8 | .009 | ||||
| Translocation 8q-arm | 10 | 73.5 | 6.9 | < .001 | 5.1 | 5.7 | .200 | ||||
| Addition 9 | 23 | 19.6 | 6.7 | .003 | 5.4 | 6.1 | .105 | ||||
| Addition 11 | 25 | 15.3 | 6.8 | .037 | 5.1 | 6.2 | .009 | ||||
| Deletion 13 | 25 | 32.1 | 6.9 | .001 | 5.2 | 6.1 | .029 | ||||
| Translocation 14q-arm | 7 | 31.4 | 6.9 | .003 | 4.3 | 5.7 | .115 | ||||
| Deletion 16q-arm | 7 | 60.4 | 7.0 | .005 | 5.1 | 5.7 | .076 | ||||
| Addition 19 | 25 | 48.2 | 6.2 | < .001 | 5.1 | 6.2 | .011 | ||||
| Deletion 19 | 2 | 134.7 | 7.5 | < .001 | 5.4 | 5.6 | .466 | ||||
| Addition 20 | 6 | 70.3 | 7.1 | .006 | 4.0 | 5.7 | .029 | ||||
| Any whole addition | 39 | 23.3 | 5.9 | < .001 | 5.1 | 6.4 | .005 | ||||
| Any whole deletion | 38 | 28.5 | 6.1 | .003 | 5.2 | 6.2 | .027 | ||||
| Any abnormality | 53 | 23.3 | 4.1 | < .001 | 5.1 | 6.6 | < .001 | ||||
| MM-MDS | 20 | 34.9 | 6.8 | < .001 | 4.3 | 6.2 | .001 | ||||
CA values listed had P < .01 in test of association between TA or TL and cytogenetic abnormality. Percentage in the second column is incidence of CA in patient population. CA indicates cytogenetic abnormalities; CA+, with cytogenetic abnormalities; CA-, without cytogenetic abnormalities; MM-MDS, myeloma cells expressing cytogenetic features seen also in myelodysplastic syndrome.